Welcome to Mesothelioma.net - Turning Hope and Faith into Action.

Nivolumab and Ipilimumab Clinical Trials

Advances in Immunotherapy drugs are showing great promise in treating difficult cancers like mesothelioma. Trials using a combination of drugs that boost the action of the immune system are ongoing and have already shown some successes. Currently there is a phase III clinical trial testing the effectiveness of nivolumab and ipilimumab in patients with pleural mesothelioma. It is being compared to standard chemotherapy with platinum drugs and pemetrexed.

Nivolumab

Made by Bristol-Myers Squibb, nivolumab is an immunotherapy drug given the brand name Opdivo. It has been tested in a number of clinical trials already and is approved for treating specific types of cancer. Current clinical trials are looking at the effectiveness and safety of nivolumab in patients with mesothelioma, usually in combination with other drugs. Nivolumab is approved by the U.S. Food and Drug Administration to treat specific advanced and metastasized cancers including:

  • Certain types of melanoma. It is also approved to prevent the recurrence of melanoma in some patients.
  • Non-small cell and small cell lung cancer.
  • Renal cell carcinoma.
  • Hodgkin’s lymphoma.
  • Head and neck cancer.
  • Urothelial cancer.
  • Colorectal cancer.
  • Hepatocellular carcinoma.

There is hope that this drug will prove in clinical trials to also be useful in treating advanced mesothelioma and to be approved for that purpose.

Nivolumab works by binding to a protein on immune system T-cells. The protein, PD-1, interacts with proteins on cancer cells, which tells it not to attack. The drug interferes with this interaction, which takes the brakes off the immune system and allows it to recognize the cancer cells as abnormal.

Ipilimumab

Marketed under the brand name Yervoy, ipilimumab is also made by Bristol-Myers Squibb and is also an immunotherapy drug. It works in a similar way to Opdivo. Ipilimumab targets the protein CTLA-4 on T-cells. This protein acts like an off switch for the immune cells. The drug blocks it and keeps the cells in the “on” state so they can attack and kill cancer cells.

Ipilimumab is not approved to treat as many cancers as nivolumab. Currently on that list is metastatic melanoma and as an additional therapy for melanoma patients who have undergone surgery to remove tumors. It is also approved to treat renal cell carcinoma, and certain types of colorectal cancer.

Combination Phase III Clinical Trial

These two drugs are approved for treating a limited number of cancer types, but patients with other kinds of cancers can potentially access them through clinical trials. For mesothelioma patients there are ongoing trials using both drugs in combination, and there may be other trials in the future.

Right now the combination therapy is being used in a phase III clinical trial. The participants in the trial are mesothelioma patients with cancers that are unresectable, which means they are not candidates for surgical removal of the bulk of tumors. The participants have also not had any other treatment; the experimental combination of nivolumab and ipilimumab is being used as a first-line therapy.

In this phase III trial patients are randomized, with some getting the new therapy and others getting the standard chemotherapy treatment of pemetrexed with carboplatin or cisplatin. It is necessary to use both types of treatment to make a comparison between the standard therapy and the new one.

Patients were accepted into the trial that were at least 18 years old and diagnosed with pleural mesothelioma, did not qualify for curative surgery, did not have another type of cancer, had metastasis to the central nervous system, and had not yet received any chemotherapy.

Earlier Clinical Trial Results with Nivolumab and Ipilimumab

The current phase III trial follows what was a promising phase II trial of the nivolumab and ipilimumab combination. That trial took place with 125 mesothelioma patients in France. That trial used the combination and tested it against the use of nivolumab alone. Another difference from the current trial was that patients in this trial had been given chemotherapy previously but without success.

The researchers achieved a disease control rate of 50 percent. This means that half of the participants had either no additional growth of tumors or actual shrinking in the tumors after several weeks of the combination treatment. More than a quarter of the patients saw tumors get smaller and the overall survival time was longer on the combination.

Potential Side Effects

Clinical trials are used to determine effectiveness of new therapies, but also to find out what side effects are caused and if they are worth the benefits of the treatment. So far, some of the more common side effects reported are hyponatremia, rashes and itchiness, fatigue, liver damage, difficulty breathing, pain, cough, nausea, anemia, constipation, vomiting, and diarrhea.

The current phase III trial is closed to new participants right now, but it may open up in the future. There is also potential that other trials using this immunotherapy combination will begin, allowing for more mesothelioma patients to benefit from it. If the trial goes well the pair of drugs could become an approved therapy for mesothelioma. If you are interested in accessing clinical trials, talk to your medical team to find out if you qualify for any studies that are currently taking patients.

Page Edited by Dave Foster

support_staff
Dave has been a mesothelioma Patient Advocate for over 10 years. He consistently attends all major national and international mesothelioma meetings. In doing so, he is able to stay on top of the latest treatments, clinical trials, and research results. He also personally meets with mesothelioma patients and their families and connects them with the best medical specialists and legal representatives available. Connect with Patient Advocate Dave Foster
Sources
  1. National Institutes of Health. U.S. National Library of Medicine. (2018 November). Study of Nivolumab Combined with Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients (CheckMate743). Retrieved from
    Retrieved from: https://clinicaltrials.gov/ct2/show/study/NCT02899299
  2. Medscape. (n.d.). Nivolumab. Retrieved from
    Retrieved from: https://reference.medscape.com/drug/opdivo-nivolumab-999989#0
  3. Medscape (n.d.). Ipilimumab. Retrieved from
    Retrieved from: https://reference.medscape.com/drug/yervoy-ipilimumab-999636#4

Get Your FREE Resources Sent Overnight

resources-shot_optimized
  • New treatment options
  • Veterans benefits & claims
  • $30 Billion asbestos trust fund information

– Or Call –
1-800-692-8608


Site Navigation

Where can I

Get Additional Help?

For over 20 years we’ve provided the best FREE resources to mesothelioma patients and loved ones. Our resources include information on the leading treatment options and best doctors in your area; lessons learned from survivors; claims and benefits specifically for Veterans; and how to access your share of billions of dollars in trust fund money.

Get Your FREE Resources Sent Overnight

resources-shot_optimized
  • New Treatment Options
  • Veteran's Benefits & Claims
  • $30 Billion Asbestos Trust Fund Information

– Or Call –
1-800-692-8608

$30 Billion Asbestos Trusts
Get Started